BSFA.LSE BSF Enterprise Plc
- Market cap
- GBX 2.01M
- P/E
- -
- P/B
- 1.04x
- ROE
- -217.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is BSFA.LSE undervalued?
Graham numberThe Graham number of BSF Enterprise Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BSF Enterprise Plc fundamental analysis
No fundamental analysis for BSF Enterprise Plc yet.
BSF Enterprise Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BSF Enterprise Plc
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.
Full company profileBSF Enterprise Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BSF Enterprise Plc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 12.9K | 57.8K | 52.8K | 75.1K |
| Gross Profit | - | - | 0.00 | -161K | -86.6K | -26.6K | -127K | -155K |
| Operating Income | -27.3K | -93.8K | -58.2K | -927K | -1.57M | -1.79M | -1.64M | -4.04M |
| EBITDA | -27.3K | -93.6K | -58.0K | -906K | -1.46M | -1.68M | -1.10M | -3.85M |
| Net Income | -94.4K | -93.9K | -58.4K | -930K | -1.50M | -1.67M | -1.11M | -3.83M |
| EPS | -0.02 | 0.00 | 0.00 | -0.02 | -0.02 | -0.02 | -0.01 | -0.03 |
| Balance Sheet | ||||||||
| Total Assets | 552K | 455K | 401K | 4.03M | 5.26M | 3.50M | 3.01M | 3.47M |
| Total Liabilities | 35.2K | 32.3K | 36.6K | 449K | 402K | 305K | 289K | 1.71M |
| Shareholders' Equity | 517K | 423K | 365K | 3.58M | 4.86M | 3.19M | 2.72M | 1.76M |
| Cash & Short-term Investments | 552K | 445K | 360K | 1.06M | 2.32M | 638K | 149K | 60.2K |
| Total Debt | - | - | - | 232K | 157K | 78.1K | - | 482K |
| Cash Flow | ||||||||
| Operating Cash Flow | -59.2K | -107K | -85.2K | -667K | -1.38M | -1.59M | -1.01M | -1.29M |
| Capital Expenditure | 10.6K | 10.6K | 3.00 | 10.6K | 64.8K | 12.0K | 10.4K | 135K |
| Free Cash Flow | -59.2K | -107K | -85.2K | -678K | -1.44M | -1.60M | -1.02M | -1.43M |
| Ratios | ||||||||
| ROE | -18.3% | -22.2% | -16.0% | -26.0% | -30.9% | -52.4% | -41.0% | -217.6% |
| ROA | -17.1% | -20.6% | -14.6% | -23.1% | -28.5% | -47.8% | -37.0% | -110.4% |
| Net Profit Margin | - | - | - | - | -11,598.2% | -2,892.2% | -2,107.4% | -5,092.5% |
| Debt to Equity | - | - | - | 0.06x | 0.03x | 0.02x | - | 0.27x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BSF Enterprise Plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | GBP 14.0K | 0.00 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on Feb 27, 2026.
Who owns BSF Enterprise Plc
- Insiders 18.70%
- Institutions 0.02%
- Public & others 81.28%
- Shares outstanding 204M
- Free float 89.3M
BSF Enterprise Plc company profile
- Company name
- BSF Enterprise Plc
- Ticker
- BSFA.LSE
- ISIN
- GB00BHNBDQ51
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- September
- Address
- 2 Portman Street, London, United Kingdom, W1H 6DU
- Phone
- 44 20 3283 4590
- Website
- bsfenterprise.com
About BSF Enterprise Plc
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.
BSF Enterprise Plc management
5- Mr. Geoffrey Robert Baker B.Com., L.L.B., M.B.A.Executive Chairman · born 1956
- Dr. Che John ConnonCEO, MD & Executive Director · born 1972
- Mr. Graham John William Duncan F.C.A.Chief Financial Officer · born 1963
- Mr. Ricardo GouveiaC.S.O
- Mr. Marcelo BravoChief Business Officer